DAY 5:
Comparing the Molnupiravir group to the placebo group, there was no
significant change in the SARS COV-2 RNA error rate. (WMD: 2.58; 95%
CI; [-0.44, 5.60] p=0.09; I²=0%) (Fig 2C)
Overall: No significant results obtained in overall
pooled analysis of molnupiravir 200mg dose. (WMD: 1.27; 95% CI;
[-0.32, 2.86] p=0.12; I²=6%) (Fig 2C)
Figure 3: Time for clearance of SARS-COV-2 or undetectable
SARS-COV-2 in the nasopharyngeal sample